Form 4 for UTHR UNITED THERAPEUTICS Corp
Accepted 2026-06-04 16:30:39 ET · period of report 2026-06-03 · accession 0001106578-26-000069 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-06-04 16:30 | 2026-06-03 | UTHR | ROTHBLATT MARTINE A | COB, CEO, Dir | M - OptEx | $146.03 | +9,500 | 50.0K | +23% | +$1.39M |
| DMT | 2026-06-04 16:30 | 2026-06-03 | UTHR | ROTHBLATT MARTINE A | COB, CEO, Dir | S - Sale+OE | $547.61 | -9,500 | 40.5K | -19% | -$5.20M |
| DT | 2026-06-04 16:30 | 2026-06-03 | UTHR | ROTHBLATT MARTINE A | COB, CEO, Dir | M - OptEx | $0.00 | -9,500 | 107.4K | -8% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-03 | M | A | 9,500 | $146.03 | 50,013 | D | — | — | (F1) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. |
| 2 | Common | Common Stock | 2026-06-03 | S | D | 401 | $543.89 | 49,612 | D | — | — | (F1) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. (F2) This transaction was executed in multiple trades at prices ranging from $543.46 to $544.45. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 3 | Common | Common Stock | 2026-06-03 | S | D | 1,139 | $545.22 | 48,473 | D | — | — | (F1) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. (F3) This transaction was executed in multiple trades at prices ranging from $544.52 to $545.50. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 4 | Common | Common Stock | 2026-06-03 | S | D | 1,050 | $546.01 | 47,423 | D | — | — | (F1) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. (F4) This transaction was executed in multiple trades at prices ranging from $545.53 to $546.47. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 5 | Common | Common Stock | 2026-06-03 | S | D | 1,664 | $546.96 | 45,759 | D | — | — | (F1) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. (F5) This transaction was executed in multiple trades at prices ranging from $546.53 to $547.51. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 6 | Common | Common Stock | 2026-06-03 | S | D | 2,226 | $548.04 | 43,533 | D | — | — | (F1) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. (F6) This transaction was executed in multiple trades at prices ranging from $547.55 to $548.42. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 7 | Common | Common Stock | 2026-06-03 | S | D | 1,956 | $549.15 | 41,577 | D | — | — | (F1) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. (F7) This transaction was executed in multiple trades at prices ranging from $548.73 to $549.72. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 8 | Common | Common Stock | 2026-06-03 | S | D | 842 | $550.06 | 40,735 | D | — | — | (F1) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. (F8) This transaction was executed in multiple trades at prices ranging from $549.79 to $550.57. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 9 | Common | Common Stock | 2026-06-03 | S | D | 80 | $551.23 | 40,655 | D | — | — | (F1) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. (F9) This transaction was executed in multiple trades at prices ranging from $550.82 to $551.63. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 10 | Common | Common Stock | 2026-06-03 | S | D | 142 | $551.97 | 40,513 | D | — | — | (F1) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. (F10) This transaction was executed in multiple trades at prices ranging from $551.87 to $552.10. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 11 | Derivative | Stock Option | 2026-06-03 | M | D | 9,500 | $0.00 | 107,410 | D | $146.03 · 2020-03-15 to 2027-03-15 | 9,500 Common Stock | (F1) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. |